Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.
The update expands EULAR’s recommendations for the IL-6 pathway beyond rheumatoid arthritis and juvenile idiopathic arthritis, into GCA, Takayasu arteritis, adult-onset Still’s disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, severe COVID-19 and other conditions.
“At the time of the first consensus statement on IL-6 and